| On researcher was part of the FDA's Drugs Advisory Committee that was responsible for reviewing Prozac, Lilly's new drug. The FDA asked him whether he might have had any conflict of interest with the pharmaceutical manufacture presenting new drugs before the Committee and this researcher answered no, although he had worked for Lilly and received money from the company.
Prozac was not found significantly more effective than the placebo, an FDA statistician suggested to Lilly that the test results be evaluated differently causing the results to come out more favorable for Prozac. Guidelines constructed by Lilly for the clinical trials excluded the reporting of "adverse experiences caused by depression" exacerbated by Prozac. The FDA admitted that this skewed the results.
Click for more on Prozac
|
print this
email this